These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

110 related articles for article (PubMed ID: 36528070)

  • 1. Potential of Orlistat to induce apoptotic and antiangiogenic effects as well as inhibition of fatty acid synthesis in breast cancer cells.
    Jovankić JV; Nikodijević DD; Milutinović MG; Nikezić AG; Kojić VV; Cvetković AM; Cvetković DM
    Eur J Pharmacol; 2023 Jan; 939():175456. PubMed ID: 36528070
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Development of a Self-Assembled Nanoparticle Formulation of Orlistat, Nano-ORL, with Increased Cytotoxicity against Human Tumor Cell Lines.
    Hill TK; Davis AL; Wheeler FB; Kelkar SS; Freund EC; Lowther WT; Kridel SJ; Mohs AM
    Mol Pharm; 2016 Mar; 13(3):720-8. PubMed ID: 26824142
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Antitumoral actions of the anti-obesity drug orlistat (XenicalTM) in breast cancer cells: blockade of cell cycle progression, promotion of apoptotic cell death and PEA3-mediated transcriptional repression of Her2/neu (erbB-2) oncogene.
    Menendez JA; Vellon L; Lupu R
    Ann Oncol; 2005 Aug; 16(8):1253-67. PubMed ID: 15870086
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Inhibition of fatty acid metabolism reduces human myeloma cells proliferation.
    Tirado-Vélez JM; Joumady I; Sáez-Benito A; Cózar-Castellano I; Perdomo G
    PLoS One; 2012; 7(9):e46484. PubMed ID: 23029529
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The effect of FASN inhibition on the growth and metabolism of a cisplatin-resistant ovarian carcinoma model.
    Papaevangelou E; Almeida GS; Box C; deSouza NM; Chung YL
    Int J Cancer; 2018 Aug; 143(4):992-1002. PubMed ID: 29569717
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Metabolic shifts induced by fatty acid synthase inhibitor orlistat in non-small cell lung carcinoma cells provide novel pharmacodynamic biomarkers for positron emission tomography and magnetic resonance spectroscopy.
    Sankaranarayanapillai M; Zhang N; Baggerly KA; Gelovani JG
    Mol Imaging Biol; 2013 Apr; 15(2):136-47. PubMed ID: 22886728
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Overexpression of fatty acid synthase in human gliomas correlates with the WHO tumor grade and inhibition with Orlistat reduces cell viability and triggers apoptosis.
    Grube S; Dünisch P; Freitag D; Klausnitzer M; Sakr Y; Walter J; Kalff R; Ewald C
    J Neurooncol; 2014 Jun; 118(2):277-287. PubMed ID: 24789255
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Anti-Tumorigenic Potential of a Novel Orlistat-AICAR Combination in Prostate Cancer Cells.
    Wright C; Iyer AKV; Kaushik V; Azad N
    J Cell Biochem; 2017 Nov; 118(11):3834-3845. PubMed ID: 28387458
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Novel signaling molecules implicated in tumor-associated fatty acid synthase-dependent breast cancer cell proliferation and survival: Role of exogenous dietary fatty acids, p53-p21WAF1/CIP1, ERK1/2 MAPK, p27KIP1, BRCA1, and NF-kappaB.
    Menendez JA; Mehmi I; Atlas E; Colomer R; Lupu R
    Int J Oncol; 2004 Mar; 24(3):591-608. PubMed ID: 14767544
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Rutin and orlistat produce antitumor effects via antioxidant and apoptotic actions.
    Saleh A; ElFayoumi HM; Youns M; Barakat W
    Naunyn Schmiedebergs Arch Pharmacol; 2019 Feb; 392(2):165-175. PubMed ID: 30465055
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Inhibition of endothelial cell proliferation and angiogenesis by orlistat, a fatty acid synthase inhibitor.
    Browne CD; Hindmarsh EJ; Smith JW
    FASEB J; 2006 Oct; 20(12):2027-35. PubMed ID: 17012255
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Fatty acid synthase inhibition results in a magnetic resonance-detectable drop in phosphocholine.
    Ross J; Najjar AM; Sankaranarayanapillai M; Tong WP; Kaluarachchi K; Ronen SM
    Mol Cancer Ther; 2008 Aug; 7(8):2556-65. PubMed ID: 18723500
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effects of Fatty Acid Synthase Inhibition by Orlistat on Proliferation of Endometrial Cancer Cell Lines.
    Wysham WZ; Roque DR; Han J; Zhang L; Guo H; Gehrig PA; Zhou C; Bae-Jump VL
    Target Oncol; 2016 Dec; 11(6):763-769. PubMed ID: 27188391
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Fatty acid synthase inhibitor orlistat induces apoptosis in T cell lymphoma: role of cell survival regulatory molecules.
    Kant S; Kumar A; Singh SM
    Biochim Biophys Acta; 2012 Nov; 1820(11):1764-73. PubMed ID: 22877747
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Tumor growth retardation and chemosensitizing action of fatty acid synthase inhibitor orlistat on T cell lymphoma: implication of reconstituted tumor microenvironment and multidrug resistance phenotype.
    Kant S; Kumar A; Singh SM
    Biochim Biophys Acta; 2014 Jan; 1840(1):294-302. PubMed ID: 24060750
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Orlistat Reduces Proliferation and Enhances Apoptosis in Human Pancreatic Cancer Cells (PANC-1).
    Sokolowska E; Presler M; Goyke E; Milczarek R; Swierczynski J; Sledzinski T
    Anticancer Res; 2017 Nov; 37(11):6321-6327. PubMed ID: 29061815
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Orlistat Resensitizes Sorafenib-Resistance in Hepatocellular Carcinoma Cells through Modulating Metabolism.
    Shueng PW; Chan HW; Lin WC; Kuo DY; Chuang HY
    Int J Mol Sci; 2022 Jun; 23(12):. PubMed ID: 35742944
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Fatty acid synthase is a key target in multiple essential tumor functions of prostate cancer: uptake of radiolabeled acetate as a predictor of the targeted therapy outcome.
    Yoshii Y; Furukawa T; Oyama N; Hasegawa Y; Kiyono Y; Nishii R; Waki A; Tsuji AB; Sogawa C; Wakizaka H; Fukumura T; Yoshii H; Fujibayashi Y; Lewis JS; Saga T
    PLoS One; 2013; 8(5):e64570. PubMed ID: 23741342
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The fatty acid synthase inhibitor orlistat reduces the growth and metastasis of orthotopic tongue oral squamous cell carcinomas.
    Agostini M; Almeida LY; Bastos DC; Ortega RM; Moreira FS; Seguin F; Zecchin KG; Raposo HF; Oliveira HC; Amoêdo ND; Salo T; Coletta RD; Graner E
    Mol Cancer Ther; 2014 Mar; 13(3):585-95. PubMed ID: 24362464
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Orlistat Displays Antitumor Activity and Enhances the Efficacy of Paclitaxel in Human Hepatoma Hep3B Cells.
    You BJ; Chen LY; Hsu PH; Sung PH; Hung YC; Lee HZ
    Chem Res Toxicol; 2019 Feb; 32(2):255-264. PubMed ID: 30667213
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.